SUMMARY Nineteen patients with multiple sclerosis were treated with azathioprine for two years. There was no evidence that treatment prevented deterioration or reduced the number or severity of the relapses when compared with 24 control patients observed over the same period.
There have been several reports of the effect of immunosuppressive drugs on multiple sclerosis (Corley, Lessner, and Larsen, 1966; Cendrowski, 1969; Tucker and Kapphahn, 1969; Cendrowski, 1971) . However these reports have been based on small numbers of patients and often no controls have been used or the effect of the drug has been assessed by the improvement or deterioration in the patient's condition over a period of months. The assessment of treatment in multiple sclerosis is notoriously difficult because of the natural history of the disease. We believe that the most reliable guide to the effectiveness of treatment is to compare the number of relapses occurring over the observed period in treated and control groups. We report here a controlled trial of the effect of azathioprine on the relapse rate in multiple sclerosis.
METHOD
In view of the possible teratogenic effects of azathioprine, women were excluded from the trial. Men with diabetes mellitus, liver, or renal disease were also excluded. Only patients able to walk with or without walking aids were included. All patients fulfilled McAlpine's criteria of definite multiple sclerosisthat is, a history of an acute retrobulbar neuritis or an episode of paraesthesia, motor weakness, double vision, unsteadiness in walking, or other symptoms known to occur in multiple sclerosis which tended to improve or clear up, followed by one or more relapses during the course of years, with, in addition, the presence of pyramidal tract or other signs indicative of multiple lesions in the central nervous system (McAlpine, Lumsden, and Acheson, 1968) .
After consenting to take part in the trial patients were allocated to control or treatment groups in balanced pairs, using a system of subgrouping, to At the start of the trial, and on subsequent occasions whenever they were examined, all the patients were scored on the Kurtzke scale which was modified slightly from the original for visual acuity (Kurtzke, 1961) .
The control group were given 50 mg ascorbic acid a day.
The treatment group before the start of azathioprine had liver function tests, blood urea, urine examination, chest radiograph, and full blood counts and thereafter a haemoglobin estimation, white blood count, and a blood film were checked initially at weekly intervals, and later at monthly intervals. (Millar, Vas, Noronha, Liversedge, and Rawson, 1967 ). Table 1 shows the mean Kurtzke scores for both groups at the start of the trial and at one and two year intervals. Apart from a slightly worse score for brain-stem function in the treated group, there is no statistical difference between the groups whose average age and duration of symptoms is also comparable. Table 2 shows the number of relapses and Table 3 the relapse scores in the two groups for the observed two year period. The Tables show no evidence to suggest that the treated group do better than the controls, either from the point of view of deterioration or reduction in the number or severity of relapses.
RESULTS

DISCUSSION
Four patients in the treated group withdrew because of gastrointestinal upset associated with the azathioprine (nausea, vomiting, and abdominal pain). One patient withdrew from each group because they left the area. These six patients are not included in the analysis.
Initially the azathioprine was dispensed as a single total daily dose and, if the patient complained of any gastrointestinal tract upset, he was advised in the first instance to divide the dose and to take it after meals; if he continued to have symptoms he was then advised to take the total dose of the drug immediately before going to bed, and this in our experience seems the best way of avoiding gastrointestinal upset with azathioprine.
At the beginning, we were rather worried that there might be a problem with infections in the treated group, but we have had no major infections at all. Only two patients showed a depression of the white count and this was of gradual onset over several weeks; the azathioprine was stopped when the white count fell below 3,600 per c.mm and within a fortnight the blood counts had returned to normal and the azathioprine was resumed. 
